Optimizing FDA’s Regulatory Oversight of Next Generation Sequencing Diagnostic Tests—Preliminary Discussion Paper I. Overview Next generation sequencing (NGS)1 comprises a collection of new technologies that allow ra - Medical genetics - Document - PDFSEARCH.IO

First Page	Meta Content
	Optimizing FDA’s Regulatory Oversight of Next Generation Sequencing Diagnostic Tests—Preliminary Discussion Paper I. Overview Next generation sequencing (NGS)1 comprises a collection of new technologies that allow ra Add to Reading List Open Document File Size: 423,78 KB Share Result on Facebook Company In Vitro Diagnostics / Clinical Laboratory / NGS / / Facility Standards Institute / Clinical Laboratory / / IndustryTerm stand-alone software / healthcare system / manufacturing / healthcare professional / learning health systems / computational processing / / MedicalCondition Illumina MiSeqDxTM Cystic Fibrosis / disease / Illumina cystic fibrosis / relevant disease / NGS-based cystic fibrosis / diseases / particular diseases / cystic fibrosis / fibrosis / / Organization National Institute of Health / FDA / Clinical Laboratory and Standards Institute / Standards Institute / Standards Development Organization / / Position representative / / Technology genomics / Diagnostic Tests / DNA sequencing / SNP / human genome / / URL www.cftr2.org / http / SocialTag Clinical research Pharmacology Food and Drug Administration Pharmaceutical industry Medical statistics Clinical trial Medical genetics Cystic fibrosis Medicine Health

Optimizing FDA’s Regulatory Oversight of Next Generation Sequencing Diagnostic Tests—Preliminary Discussion Paper I. Overview Next generation sequencing (NGS)1 comprises a collection of new technologies that allow raAdd to Reading List